MonoSol Rx, Vestiq deal
Vestiq acquired exclusive, U.S. rights to Zuplenz ondansetron oral soluble film from MonoSol. MonoSol received an undisclosed upfront payment and is eligible for double-digit royalties. Zuplenz is approved to prevent nausea and vomiting associated with radiotherapy and highly or moderately emetogenic cancer chemotherapy and postoperative nausea and vomiting. The selective serotonin (5-HT3) receptor antagonist is formulated using MonoSol's PharmFilm thin film technology. In 2011, MonoSol and partner APR Applied Pharma Research S.A. (Balerna, Switzerland) said they would seek a new commercial partner after MonoSol reacquired U.S. rights to Zuplenz from the Strativa Pharmaceuticals subsidiary of Par Pharmaceutical Cos. Inc. (NYSE:PRX, Woodcliff Lake, N.J.). Vestiq and MonoSol declined to disclose details (see BioCentury, June 23, 2008 & July 18, 2011). ...